go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

AstraZeneca Pharmaceuticals (Ireland) Ltd

AstraZeneca Pharmaceuticals (Ireland) Ltd
College Park House, 20 Nassau Street, Dublin 2,
Telephone: +353 1 609 7100
Fax: +353 1 679 6650
Medical Information Direct Line: 1800 800 899 Freephone
Medical Information e-mail: medical.informationuk@astrazeneca.com
Customer Care direct line: +353(0)1 609 7100 Supply & non-medical enquiries
Medical Information Facsimile: +44 (0)1582 838 003
Summary of Product Characteristics last updated on medicines.ie: 05/08/2008
SPC Tenormin Tablets 25mg, 50mg & 100mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 05/08/2008 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   07/2008
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 4.4
New sentence added:
May cause a hypersensitivity reaction including angioedema and urticaria.
 
Section 4.5
following new text added and deleted:
Class I anti-arrhythmic drugs (e.g. disopyramide) and amiodarone may have a potentiating effect on atrial-conduction time and induce negative inotropic effect.Caution must be exercised when prescribing a beta-blocker with Class 1 antiarrhythmic agents such as disopyramide.
 
Section 4.8
New text added is in red:
The following undesired events, listed by body system, have been reported with the following frequencies: very common (³10%), common (1–9.9%), uncommon
 (0.1–0.9%), rare (0.01–0.09%), very rare (<0.01%) including isolated reports, not known (cannot be estimated from the available data).
 
Skin and subcutaneous tissue disorders:
 Rare:            Alopecia, psoriasiform skin reactions, exacerbation of psoriasis, skin rashes.
Not known:            Hypersensitivity reactions, including angioedema and urticaria.
 
Section 10
Date updated to 15th July 2008
Updated on 10/12/2007 and displayed until 05/08/2008
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   11/2007
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 2

New text added in bold:

25 mg Tablets

Each tablet contains 25 mg Atenolol.

           

50 mg Tablets

Each tablet contains 50 mg Atenolol.

           

100 mg Tablets

Each tablet contains 100 mg Atenolol.

Each 100 mg tablet contains 0.8 mg Sunset Yellow Lake (E110).

 

For a full list of excipients, see section 6.1.

 

Section 3

New sentence added to end of section 3:

The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

           

 

Section 9

Date changed to 13 August 2007:

Tenormin 25 mg Film-coated Tablets

14 August 1992/13 August 2007  

 

Tenormin 50 mg Film-coated Tablets

04 February 1976/13 August 2007

 

Tenormin 100 mg Film-coated Tablets

17 May 1978/13 August 2007

 

 

Section 10

Date changed to 30th November 2007   
Updated on 20/09/2006 and displayed until 10/12/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text
  • Change from the BAN of the active substance to the rINN
Date of revision of text on the SPC:   06/2006
Legal Category:   prescription only

Free-text change information supplied by the pharmaceutical company

Section 4.2

-         Reference to intravenous Tenormin has been removed.

-         The paragraphs on ‘Early’ and ‘Late’ Intervention after Myocardial Infarction have been merged into one paragraph.

 

Section 4.4

-         Paragraphs on the withdrawal and discontinuation of therapy before surgery have been added.

The following warnings have been added:

-         Tenormin ‘may mask the symptoms of hypoglycaemia, in particular, tachycardia’.

-         Tenormin ‘should only be given to patients with psoriasis after careful consideration, as psoriasis may be aggravated’.

-         ‘Since Tenormin is excreted via the kidneys, dosage should be reduced in patients with a creatinine clearance of below 35 ml/min/1.73  m2’.

-         ‘As with other beta-blockers, in patients with a phaeochromocytoma, an alpha-blocker should be given concomitantly’.

 

Section 4.5

-         Drug class headings have been added to each paragraph.

 

Section 4.6

-         Neonatal bradycardia has been added.

 

Section 4.8

-         Frequencies have been added to the undesired events table.

 

Section 5.2

      -    Reference to intravenous administration has been removed.
Updated on 10/02/2005 and displayed until 20/09/2006
Reasons for adding or updating:
  • Change to section 1 - Name of medicinal product
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text
Updated on 18/06/2003 and displayed until 10/02/2005
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Atenolol

Versions

 
05/08/2008 to Current
10/12/2007 to 05/08/2008
20/09/2006 to 10/12/2007
10/02/2005 to 20/09/2006
18/06/2003 to 10/02/2005
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo